Multiple Myeloma Coverage from Every Angle

Purging Multiple Myeloma Cells Using Bortezomib and Lenalidomide

By: Joseph Fanelli
Posted: Wednesday, May 29, 2019

Treatment using bortezomib and lenalidomide against RPMI-8226 multiple myeloma cells may act as a purging method in removing contaminated plasma cells, according to preliminary study findings published in the Journal of Blood Medicine. If applicable to patient-derived stem cell grafts, this strategy may potentially improve the cure rate in patients with multiple myeloma, concluded A-Jin Lee, MD, and Sang-Gyung Kim, MD, of the Daegu Catholic University School of Medicine, Daegu, Korea, and colleagues.

“RPMI-8226 cells expressed two aberrant phenotypes of CD19CD56+,” the authors observed. “These clonal cells were effectively removed by treatment with bortezomib and lenalidomide.”

The authors treated the human myeloma cell line RPMI-8226 with bortezomib or lenalidomide, whereas the mixture of the human peripheral blood monocular cell line PCS-800-011 and RPMI-8226 were treated with bortezomib or lenalidomide for 24 hours. The efficacy of purging myeloma cells was evaluated by eight-color flow-cytometric analysis.

After a 24-hour incubation with bortezomib at 10, 20, 40, 80, and 160 nmol/L, RPMI-8226 cells displayed growth inhibition of 5.45% ± 0.07%, 47.15% ± 1.20%, 57.15% ± 0.21%, 72.35% ± 0.07%, and 84.75% ± 0.49%, respectively. A 24-hour incubation with lenalidomide in RPMI-8226 cells exhibited growth inhibition of 5.45% ± 0.07%, 7.55% ± 0.07%, 9.75% ± 0.35%, 18.25% ± 0.21%, and 39.75% ± 0.78% at 200, 400, 800, 1,600, and 3,200 nmol/L, respectively.

The authors also observed that 40 nmol/L of bortezomib and 3,200 nmol/L of lenalidomide for 24 hours effectively removed CD38+CD138+ cells from peripheral mononuclear cells. Additionally, RPMI-8226 cells showed an aberrant phenotype CD56+/CD45.

“Our results indicated that both drugs [bortezomib and lenalidomide] inhibited the proliferation of RPMI-8226 cells in a dose-dependent manner,” authors concluded.

Disclosure: The study authors reported no conflicts of interest.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.